Teva-Erlotinib 25 mg

Teva-Erlotinib 25 mg tablets are a targeted therapy option for certain types of cancer. This oral medication is designed to inhibit specific proteins involved in cancer cell growth, offering a precise approach to treatment.

Teva-Erlotinib 25 mg tablets are primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. Erlotinib, the active ingredient, works by targeting the epidermal growth factor receptor (EGFR), which plays a role in cancer cell proliferation. This medication is often considered when other treatments have not been effective or when the cancer has specific genetic markers.

Common effects of Teva-Erlotinib 25 mg tablets may include skin rash, diarrhea, and fatigue. Some individuals might also experience appetite loss, nausea, or dry skin. These effects can vary in intensity and duration among users.

Teva-Erlotinib 25 mg tablets should be handled with care, especially for individuals with pre-existing liver or kidney conditions. It is important to follow the advice of a healthcare provider regarding the use of this medication. Regular monitoring may be necessary to manage potential side effects.

Teva-Erlotinib 25 mg tablets may interact with certain medications, including those that are metabolized by the liver's cytochrome P450 system. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, grapefruit and grapefruit juice should be avoided as they can affect the metabolism of erlotinib.